Liver transplantation.

Area of Science:

• Hepatology
• Transplant Surgery
• Infectious Diseases

Background:

• Increasing organ transplant demand necessitates improved recipient selection and outcome prediction.
• Current immunosuppression strategies balance graft survival with long-term side effects.
• Viral infections pose significant risks to liver transplant recipients.

Purpose of the Study:

• To review current strategies for managing viral diseases in liver transplant recipients.
• To assess the effectiveness of antiviral therapies in preventing and treating post-transplant viral infections.
• To discuss the impact of viral recurrence on long-term graft and patient survival.

Main Methods:

• Review of current literature on immunosuppression and viral disease management in liver transplantation.
• Analysis of prophylactic and therapeutic strategies for cytomegalovirus, hepatitis B, and hepatitis C.
• Evaluation of treatment outcomes, including patient survival, graft success, and disease recurrence.

Main Results:

• Prophylactic antiviral therapy effectively reduces cytomegalovirus disease incidence in high-risk patients.
• Lamivudine shows potential in limiting hepatitis B virus recurrence, offering a cost-effective alternative.
• While overall survival is good for hepatitis C, severe recurrent disease remains a concern, with interferon showing some benefit.

Conclusions:

• Optimizing recipient selection and managing viral infections are crucial for liver transplant success.
• Targeted antiviral strategies are vital for mitigating morbidity and mortality associated with cytomegalovirus and recurrent hepatitis.
• Further research into antiviral therapies is needed for hepatitis C patients to improve long-term outcomes.